Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population New data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in earlier disease settings Basel, Septembe ...